Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Spalding, Maroya D ^a   Eyase, Fredrick L ^b   Akala, Hoseah M ^b   Bedno, Sheryl A ^c   Prigge, Sean T ^a   Coldren, Rodney L ^c   Moss, William J ^a   Waters, Norman C ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b U S ARMY   (United States)

^c Uniformed Services University of the Health Sciences   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; CHLORCYCLOGUANIL; CHLOROQUINE; DAPSONE; MEFLOQUINE; MOLECULAR MARKER; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; FOLIC ACID ANTAGONIST; PROTOZOAL PROTEIN; QUINOLONE DERIVATIVE; SULFADOXINE-PYRIMETHAMINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CODON; DRUG DETERMINATION; FOLLOW UP; GENOTYPE; IC 50; IN VITRO STUDY; KENYA; MUTATION; NONHUMAN; PARASITE ISOLATION; PARASITE PREVALENCE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALARIA; MISSENSE MUTATION; PARASITOLOGY; PLASMODIUM; PREVALENCE;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; CODON; CROSS-SECTIONAL STUDIES; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; FOLIC ACID ANTAGONISTS; GENOTYPE; HUMANS; INHIBITORY CONCENTRATION 50; KENYA; MALARIA; MUTATION, MISSENSE; PARASITIC SENSITIVITY TESTS; PLASMODIUM; PREVALENCE; PROTOZOAN PROTEINS; PYRIMETHAMINE; QUINOLONES; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 78549234725     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-338     Document Type: Article

References (57)

1. Kenya Medical Research Institute Kenya Malaria Fact Sheet. http://www.kemri.org/index.php/help-desk/search/diseases-a-conditions/ 29-malaria/113-kenya-malaria-fact-sheet
2. Using evidence to change antimalarial drug policy in Kenya. R Shretta J Omumbo B Rapuoda RW Snow, Trop Med Int Health 2000 5 755 764 10.1046/j.1365-3156.2000.00643.x 11123822
3. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. A Amin D Zurovac B Kangwana J Greenfield D Otieno W Akhwale R Snow, Malar J 2007 6 72 10.1186/1475-2875-6-72 17535417
4. Factors determining anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya. CA Watsierah WG Jura H Oyugi B Abong'o C Ouma, Malar J 2010 9 295 10.1186/1475-2875-9-295 20977741
5. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. FO ter Kuile AM van Eijk SJ Filler, JAMA 2007 297 2603 2616 10.1001/jama.297.23.2603 17579229
6. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. R Kobbe C Kreuzberg S Adjei B Thompson I Langefeld PA Thompson HH Abruquah B Kreuels M Ayim W Busch F Marks K Amoah E Opoku CG Meyer O Adjei J May, Clin Infect Dis 2007 45 16 25 10.1086/518575 17554695
7. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? RD Gosling I Carneiro D Chandramohan, Trop Med Int Health 2009 14 1003 1010 10.1111/j.1365-3156.2009.02303.x 19558374
8. Intermittent preventive treatment against malaria in infants in Gabon - a randomized, double-blind, placebo-controlled trial. MP Grobusch B Lell NG Schwarz J Gabor J Dornemann M Potschke S Oyakhirome GC Kiessling M Necek MU Langin P Klein Klouwenberg A Klopfer B Naumann H Altun ST Agnandji J Goesch M Decker CL Salazar C Supan DU Kombila L Borchert KB Koster P Pongratz AA Adegnika I Glasenapp S Issifou PG Kremsner, J Infect Dis 2007 196 1595 1602 10.1086/522160 18008242
9. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. E Macete P Aide JJ Aponte S Sanz I Mandomando M Espasa B Sigauque C Dobano S Mabunda M DgeDge P Alonso C Menendez, J Infect Dis 2006 194 276 285 10.1086/505431 16826474
10. Intermittent preventive treatment in infants as a mean of malaria control: a randomized, double-blind, and placebo-controlled trial in northern Ghana. FP Mockenhaupt K Reither P Zanger F Roepcke I Danquah E Saad P Ziniel SY Dzisi M Frempong P Agana-Nsiire F Amoo-Sakyi R Otchwemah JP Cramer SD Anemana E Dietz U Bienzle, Antimicrob Agents Chemother 2007 AC.00513 00507
11. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. D Schellenberg C Menendez E Kahigwa J Aponte J Vidal M Tanner H Mshinda P Alonso, Lancet 2001 357 1471 1477 10.1016/S0140-6736(00)04643-2 11377597
12. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. A Nzila-Mounda EK Mberu CH Sibley CV Plowe PA Winstanley WM Watkins, Antimicrob Agents Chemother 1998 42 164 169 9449279
13. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RA Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 388 10.1086/338566 11807721
14. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. SJ Foote D Galatis AF Cowman, Proc Natl Acad Sci USA 1990 87 3014 3017 10.1073/pnas.87.8.3014 2183221
15. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. CV Plowe JF Cortese A Djimde OC Nwanyanwu WM Watkins PA Winstanley JG Estrada-Franco RE Mollinedo JC Avila JL Cespedes D Carter OK Doumbo, J Infect Dis 1997 176 1590 1596 10.1086/514159 9395372
16. Emergence of a dhfr mutation conferring high level drug resistance in Plasmodium falciparum populations from southwest Uganda. C Lynch R Pearce H Pota J Cox A Abeku Tarekegn J Rwakimari I Naidoo J Tibenderana C Roper, J Infect Dis 2008 197 1598 1604 10.1086/587845 18471065
17. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. AM McCollum AC Poe M Hamel C Huber Z Zhou YP Shi P Ouma J Vulule P Bloland L Slutsker JW Barnwell V Udhayakumar AA Escalante, J Infect Dis 2006 194 189 197 10.1086/504687 16779725
18. Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya. MJ Oesterholt M Alifrangis CJ Sutherland SA Omar P Sawa C Howitt LC Gouagna RW Sauerwein T Bousema, PLoS ONE 2009 4 4364 10.1371/journal.pone.0004364 19194499
19. Drug Resistance Maps. http://www.drugresistancemaps.org/
20. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. T Triglia JGT Menting C Wilson AF Cowman, Proc Natl Acad Sci USA 1997 94 13944 13949 10.1073/pnas.94.25.13944 9391132
21. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. T Triglia P Wang PF Sims JE Hyde AF Cowman, Embo J 1998 17 3807 3815 10.1093/emboj/17.14.3807 9669998
22. Mutations associated with sulphadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. A Alker V Mwapasa A Purfield S Rogerson M Molyneux D Kamwendo E Tadesse E Chaluluka S Meshnick, Antimicrob Agents Chemother 2005 49 3919 3921 10.1128/AAC.49.9.3919- 3921.2005 16127071
23. Molecular surveillance of mutations in dihydrofolate reductase and dihydropterate synthase genes of Plasmodium falciparum in Ethiopia. T Gebru-Woldearegai A Hailu MP Grobusch JFJ Kun, Am J Trop Med Hyg 2005 73 1131 1134 16354825
24. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. S Biswas A Escalante S Chaiyaroj P Angkasekwinai AA Lal, Trop Med Int Health 2000 5 737 743 10.1046/j.1365-3156. 2000.00632.x 11044269
25. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. DA Fidock T Nomura AK Talley RA Cooper SM Dzekunov MT Ferdig LM Ursos AB Sidhu B Naude KW Deitsch XZ Su JC Wootton PD Roepe TE Wellems, Mol Cell 2000 6 861 871 10.1016/S1097-2765(05)00077-8 11090624
26. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. RN Price AC Uhlemann A Brockman R McGready E Ashley L Phaipun R Patel K Laing S Looareesuwan NJ White F Nosten S Krishna, Lancet 2004 364 438 447 10.1016/S0140-6736(04)16767-6 15288742
27. Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. FP Mockenhaupt S Ehrhardt TA Eggelte P Agana-Nsiire K Stollberg A Mathieu M Markert RN Otchwemah U Bienzle, Ann Trop Med Parasitol 2005 99 723 732 10.1179/136485905X75395 16297285
28. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. ABS Sidhu SG Valderramos DA Fidock, Molecular Microbiology 2005 57 913 926 10.1111/j.1365-2958.2005. 04729.x 16091034
29. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. C Dokomajilar SL Nsobya B Greenhouse PJ Rosenthal G Dorsey, Antimicrob Agents Chemother 2006 50 1893 1895 10.1128/AAC.50.5.1893-1895.2006 16641472
30. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. GS Humphreys I Merinopoulos J Ahmed CJ Whitty TK Mutabingwa CJ Sutherland RL Hallett, Antimicrob Agents Chemother 2007 51 991 997 10.1128/AAC.00875-06 17194834
31. A molecular marker for chloroquine-resistant falciparum malaria. A Djimdé OK Doumbo JF Cortese K Kayentao S Doumbo Y Diourte A Dicko X-z Su T Nomura DA Fidock TE Wellems CV Plowe D Coulibaly, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152
32. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. JG Kublin JF Cortese EM Njunju GRA Mukadam JJ Wirima PN Kazembe AA Djimde B Kouriba TE Taylor CV Plowe, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863
33. Return of chloroquine antimalarial efficacy in Malawi. MK Laufer PC Thesing ND Eddington R Masonga FK Dzinjalamala SL Takala TE Taylor CV Plowe, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247
34. Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. A Mbaisi P Liyala F Eyase R Achilla H Akala J Wangui J Mwangi F Osuna U Alam BL Smoak JM Davis DE Kyle RL Coldren C Mason NC Waters, Antimicrob Agents Chemother 2004 48 3598 3601 10.1128/AAC.48.9.3598-3601.2004 15328137
35. Plasmodium falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroato synthase genes by PCR and restriction digestion. M Duraisingh J Curtis D Warhurst, Exp Parasitol 1998 89 1 8 10.1006/expr.1998. 4274 9603482
36. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum. P Wang DR Brooks PFG Sims JE Hyde, Molecular and Biochemical Parasitology 1995 71 115 125 10.1016/0166-6851(95)00041-X 7630375
37. Estimation of numbers of malaria clones in blood samples. WG Hill HA Babiker, Proc Biol Sci 1995 262 249 257 10.1098/rspb.1995.0203 8587883
38. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. HK Webster EF Boudreau K Pavanand K Yongvanitchit LW Pang, Am J Trop Med Hyg 1985 34 228 235 3885770
39. Comparison of in vivo and in vitro tests of resistance in patients treated with choroquine in Yaounde, Cameroon. P Ringwald LK Basco, Bull World Health Organ 1999 77 34 43 10063659
40. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. LK Basco J Le Bras, Am J Trop Med Hyg 1992 47 521 527 1443351
41. In vitro activities of Benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. B Pradines A Tall T Fusai A Spiegel R Hienne C Rogier JF Trape J Le Bras D Parzy, Antimicrob Agents Chemother 1999 43 418 420 9925550
42. In vitro Activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. LK Basco O Ramiliarisoa JL Bras, Am J Trop Med Hyg 1994 50 193 199 8116812
43. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. P Wang C-S Lee R Bayoumi A Djimde O Doumbo G Swedberg LD Dao H Mshinda M Tanner WM Watkins PF Sims JE Hyde, Mol Biochem Parasitol 1997 89 161 177 10.1016/S0166-6851(97)00114-X 9364963
44. Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. EK Mberu AM Nzila E Nduati A Ross SM Monks GO Kokwaro WM Watkins C Hopkins Sibley, Exp Parasitol 2002 101 90 96 10.1016/S0014-4894(02)00108-X 12427462
45. Chloroquine resistance before and after its withdrawal in Kenya. L Mwai E Ochong A Abdirahman S Kiara S Ward G Kokwaro P Sasi K Marsh S Borrmann M Mackinnon A Nzila, Malar J 2009 8 106 10.1186/1475-2875-8-106 19450282
46. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. M Alifrangis JP Lusingu B Mmbando MB Dalgaard LS Vestergaard D Ishengoma IF Khalil TG Theander MM Lemnge IC Bygbjerg, Am J Trop Med Hyg 2009 80 523 527 19346369
47. Population dynamics of malaria vectors in western Kenya highlands. B Ndenga A Githeko E Omukunda G Munyekenye H Atieli P Wamai C Mbogo N Minakawa G Zhou G Yan, J Med Entomol 2006 43 200 206 10.1603/0022-2585(2006)043[0200: PDOMVI]2.0.CO;2 16619599
48. Changing malaria intervention coverage, transmission and hospitalization in Kenya. EA Okiro VA Alegana AM Noor RW Snow, Malar J 2010 9 285 10.1186/1475-2875-9-285 20946689
49. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. I Khalil AM Ronn M Alifrangis HA Gabar GM Satti IC Bygbjerg, Am J Trop Med Hyg 2003 68 586 589 12812351
50. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. JK Iyer WK Milhous JF Cortese JG Kublin CV Plowe, The Lancet 2001 358 1066 1067 10.1016/S0140-6736(01)06201-8 (Pubitemid 32925132)
51. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. F Mockenhaupt T Bousema T Eggelte J Schreiber S Ehrhardt N Wassilew R Otchwemah R Sauerwein U Bienzle, Trop Med Int Health 2005 10 901 908 10.1111/j.1365-3156.2005.01471.x 16135198
52. Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. I Naidoo C Roper, Trends Parasitol 2010 26 447 456 10.1016/j.pt.2010.05.001 20728060
53. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. WE Harrington TK Mutabingwa A Muehlenbachs B Sorensen MC Bolla M Fried PE Duffy, Proc Natl Acad Sci USA 2009 106 9027 9032 10.1073/pnas.0901415106 19451638
54. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. S Gesase RD Gosling R Hashim R Ord I Naidoo R Madebe JF Mosha A Joho V Mandia H Mrema E Mapunda Z Savael M Lemnge FW Mosha B Greenwood C Roper D Chandramohan, PLoS ONE 2009 4 4569 10.1371/journal.pone.0004569 19238219
55. Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. C Karema M Imwong CI Fanello K Stepniewska A Uwimana S Nakeesathit A Dondorp NP Day NJ White, Antimicrob Agents Chemother 2010 54 477 483 10.1128/AAC.00498-09 19841150
56. Short report: Association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. E Ochong I Van den Broek K Keus A Nzila, Am J Trop Med Hyg 2003 69 184 187 13677373
57. Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector. A Amin R Snow, Malar J 2005 4 36 10.1186/1475-2875-4-36 16042815